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Abstract
Research on the biology of malaria parasites has greatly benefited from the application of reverse genetic technologies, in
particular through the analysis of gene deletion mutants and studies on transgenic parasites that express heterologous or
mutated proteins. However, transfection in Plasmodium is limited by the paucity of drug-selectable markers that hampers
subsequent genetic modification of the same mutant. We report the development of a novel ‘gene insertion/marker out’
(GIMO) method for two rodent malaria parasites, which uses negative selection to rapidly generate transgenic mutants
ready for subsequent modifications. We have created reference mother lines for both P. berghei ANKA and P. yoelii 17XNL
that serve as recipient parasites for GIMO-transfection. Compared to existing protocols GIMO-transfection greatly simplifies
and speeds up the generation of mutants expressing heterologous proteins, free of drug-resistance genes, and requires far
fewer laboratory animals. In addition we demonstrate that GIMO-transfection is also a simple and fast method for genetic
complementation of mutants with a gene deletion or mutation. The implementation of GIMO-transfection procedures
should greatly enhance Plasmodium reverse-genetic research.
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Introduction
Reverse genetic technologies have been widely applied to gain
an understanding of the function of genes in Plasmodium and to
provide insight into the biology of malaria parasites and
interactions with their hosts (for reviews see [1–3]. The availability
of efficient genetic modification technologies for the rodent
malaria parasites P. berghei and P. yoelii and the possibilities for
analysis of these parasites throughout the complete life cycle have
made P. berghei and P. yoelii the most frequently used models for
analysis of gene function [2]. Targeted disruption or mutation of
genes coupled with protein tagging has provided insight into
Plasmodium gene function and parasite protein expression,
localization and transport. Reverse genetics is not only applied
to understand Plasmodium gene function by gene deletion but is also
increasingly being used to generate parasites that express
heterologous proteins, for example parasites having transgenes
introduced into their genome to encode fluorescent or luminescent
reporter proteins. Such reporter parasites have been instrumental
in the visualization and analysis of parasite-host interactions in
real-time in vitro and in vivo [4–6]. The use of mutant parasites to
investigate host-parasite interactions as well as parasite gene
function requires genetic modification systems that are flexible and
easy to perform. The application of reverse genetics in P. berghei
and P. yoelii is however restricted by the limited number of drug
resistance genes (permitting the selection of transformed parasites)
that are currently available. This low number of selection markers
hampers and slows down successive modifications in the genome
of the same parasite line. Currently only two resistance gene/drug
combinations exist for use in rodent malaria parasites that can be
used in successive transfections, specifically dhfr-ts/pyrimethamine
and hdhfr/WR99210 [7]. Since both drug-selection markers confer
resistance against pyrimethamine, the introduction of consecutive
genetic modifications in the same parasite can only be performed
by first selecting with pyrimethamine followed by WR99210
selection [7]. In order to circumvent the problem of limited drug-
selection markers, GFP has been utilized as a selection marker and
permits the selection of transformed P. berghei parasites by flow
cytometry [8,9]. In addition, a method has been developed for
removing drug-selection markers from transformed P. berghei
parasites by utilizing the yeast fcu (yfcu) selection marker and
negative selection with the drug 5-fluorocytosine (5-FC) [10],
which kills all parasites expressing yfcu. In this method transformed
parasites expressing the fusion gene hdhfr::yfcu are first selected by
positive selection with pyrimethamine. Subsequently, negative
selection with 5-FC is applied to select for marker-free parasites
that have ‘spontaneously’ lost the hdhfr::yfcu marker from their
genome, achieved by a homologous recombination/excision event
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expressing mutants by flow cytometry and selection of ‘spontane-
ous’ marker-free mutants by negative selection have their
limitations. They are laborious and time consuming, and also
require the use of many extra animals as additional cloning steps in
mice are required; therefore these methods are not commonly
used for successive genetic modifications or for complementation
studies [11].
Here we report the development and application of a novel
‘gene insertion/marker out’ (GIMO) system for transfection of two
rodent malaria parasites, P. berghei and P. yoelii. For both species we
have created reference mother lines that contain the hdhfr::yfcu
selection marker stably integrated into the silent 230p genomic
locus. We show that transfection of these mother lines with DNA-
constructs that target the modified 230p locus, followed by
negative selection of transformed parasites with 5-FC is a simple
and fast method to generate mutants that stably express
heterologous proteins and are free of drug-selectable markers.
These mother lines are therefore useful tools to generate a wide
range of mutants expressing reporter and/or other heterologous
proteins (under the control of different promoters) without
restricting subsequent modification of the genome of these
parasites. In addition, we demonstrate that GIMO-transfection is
a simple and fast method to genetically complement, restoring the
wild-type genotype of parasite mutants with a gene deletion or
gene mutation. Importantly, GIMO transfection can be easily
partnered for use with a recently developed ‘recombineering’
system for high-throughput, genome wide and highly efficient
generation of gene targeting constructs [12].
Results
Generation of the P. berghei and P. yoelii ‘gene insertion/
marker out’ (GIMO) mother lines
For both P. berghei ANKA and P. yoelii 17XNL transgenic
parasites were generated that express a fusion of a drug
resistance gene and a drug sensitivity gene, the so called
postive-negative selectable marker (SM), constitutively expressed
by the P. berghei eef1a promoter (Figure 1A). Specifically, these
parasites contain a fusion gene of hdhfr (human dihydrofolate
reductase; positive SM) and yfcu (yeast cytosine deaminase and uridyl
phosphoribosyl transferase; negative SM) stably integrated into the
230p locus (PBANKA_030600 in P. berghei and PY03857 in P.
yoelii) through double cross-over recombination. These lines are
named GIMO mother lines (gene insersion/marker out); for P.
berghei GIMOPbANKA (line 1596cl1) and for P. yoelii GIMOPy17X
(line 1923cl1). Both GIMO mother lines were cloned after
transfection by positive selection with pyrimethamine. Correct
integration of the hdhfr::yfcu selectable marker cassette in the
230p locus was demonstrated by PCR and Southern analysis of
chromosomes separated by pulse-field gel electrophoresis
(Figure 1B and 1C). The multiplication rate of asexual blood
stages per 24 h as determined in mice infected with a single
parasite [13], gametocyte production and production of oocysts
and sporozoites were identical to those of the parent P. berghei
and P. yoelii lines (data not shown). These GIMO mother lines
are used for introduction of transgenes into the modified 230p
locus through transfection with constructs that target the 230p
locus. These constructs insert into the 230p locus (‘gene
insertion’), thereby removing the hdhfr::yfcu selectable marker
(‘marker out’) from the genome of the mother lines. Transgenic
parasites that are marker-free are subsequently selected by
applying negative drug selection using 5-FC (see below).
Assessing the efficiency of GIMO-transfection to select
transgene expressing, drug-selectable marker-free P.
berghei parasites
We generated a test DNA-construct containing a transgene
expression-cassette to test the efficiency of selection of transgenic
mutants through the application of negative selection using 5-FC
after transfection into the GIMOPbANKA mother line. This
construct contains the mCherry gene under the control of the
constitutive eef1a promoter and 230p targeting sequences
(Figure 2A) and lacks a drug selectable marker cassette. This
DNA-construct, pL1628, targets the same regions in the 230p
locus in which hdhfr::yfcu selection cassette was introduced in the
GIMOPbANKA mother line (Figure 2A). Transfection of
GIMOPbANKA (exp. 1645) was performed using standard
procedures [14] except that after transfection negative drug
selection was applied instead of positive drug selection. This
negative selection was performed by treating mice that were
infected with transfected parasites with the drug 5-FC for 4
consecutive days (one dose per day of 10 mg), starting 24 hours
after transfection.
Transfected parasites of line 1645 were collected at day 7 and 8
after transfection (at a parasitemia of 0.5–3%) for phenotype and
genotype analyses. Diagnostic PCR and Southern analysis of
separated chromosomes confirmed the correct integration of the
test construct and simultaneous removal of the hdhfr::yfcu selection
cassette (Figure 2B). Analysis of mCherry expression by fluores-
cence microscopy in blood stage parasites of line 1645 showed that
.90% of the parasites expressed mCherry (Figure 2C). Quanti-
fication of the percentage of mCherry-expressing parasites was
performed by FACS analysis of mature schizonts collected from
overnight blood stage cultures. Expression of transgenes, such as
mCherry, under the control of the eef1a promoter increases with the
maturation of parasites inside blood cells and therefore FACS
quantification is improved by analysing mature schizont stages
(these stages are selected based on Hoechst-fluorescence) [15].
FACS analysis confirmed that .90% (93%61.1 Figure 2D) of the
schizonts were mCherry positive. Since episomal constructs cannot
be maintained during selection in GIMO-transfected parasites (see
Discussion), these analyses demonstrate that GIMO-transfection
permits the selection parasites that express transgenes and are
marker-free.
To further investigate the efficiency of the GIMO system, we
performed a set of independent transfections with the DNA-
construct pL1628 (exp. 1794–1799) in the GIMOPbANKA mother
line. In these experiments transfected parasites were selected
using negative selection as described above and mCherry
expression analysed by FACS (Figure 3A). In 5 out of 6
transfection experiments, the percentage of mCherry-expressing
parasites was higher than 75%, whereas in one experiment (exp.
1798) 32% of schizonts were mCherry positive (Figure 3A). The
presence of mCherry negative parasites in the drug-selected
population indicates that non-transformed parasites survived the
drug-selection but presumably still carry the hdhfr::yfcu cassette.
We therefore analysed the genotype of the selected populations
of all experiments by quantitative real-time PCR (qPCR) and
Southern analysis of separated chromosomes to determine the
ratio between parasites with and without hdhfr::yfcu. For qPCR,
CT values of amplification of mCherry, hdhfr::yfcu and the
control hsp70 gene were determined and the percentage of
mCherry positive parasites was calculated as the relative ratio
between mCherry and hdhfr::yfcu using the 2
2DDCT method [16].
The percentage of mCherry positive parasites based on qPCR
correlated well with the percentage determined by FACS
analysis (Figure 3A). Southern analysis also showed that in the
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the hdhfr::yfcu gene (Figure 3B). These observations indicate that
the application of negative selection after transfection of
GIMOPbANKA, while it highly enriches for transformed parasites,
it does not generate a pure population of marker-free parasites.
Therefore, parasite cloning after negative selection is an essential
step in GIMO-transfection in order to obtain correctly
transformed parasites that express the transgene and are drug-
selectable marker free.
Generation of a P. yoelii reporter line, PyGFP-luccon, which
is marker-free and expresses a GFP-luciferase fusion
protein, by GIMO-transfection
The application of negative selection to genetic modification of
P. yoelii has not been reported. To test the possibility to select P.
yoelii parasites lacking hdhfr::yfcu from a population of hdhfr::yfcu-
containing parasites by negative selection, we generated a
construct (pL1847) that targets the modified py230p locus of the
Figure 1. Generation and genotype analyses of P. berghei and P. yoelii GIMO mother lines. (A) Schematic representation of the constructs
used to introduce the positive-negative selectable maker cassette in the P. berghei (PbANKA) or P. yoelii (Py17XNL) 230p locus. DNA constructs pL1603
(targeting P. berghei 230p, PBANKA_030600) and pL1805 (targeting P. yoelii 230p, PY03857) containing a fusion of the positive drug selectable marker
hdhfr (human dihydrofolate reductase) and negative marker yfcu (yeast cytosine deaminase and uridyl phosphoribosyl transferase) under the control of
the eef1a promoter target the 230p locus at the target regions (hatched boxes) by double cross-over homologous recombination. Location of primers
used for PCR analysis and sizes of PCR products are shown (see Table S2 for all primer sequences). (B) Diagnostic PCR and Southern analysis of PFG-
separated chromosomes confirming correct integration of the construct in the P. berghei mother line GIMOPbANKA:5 9 integration PCR (59 int; primers
5510/3189), 39 integration PCR (39 int; primers 4239/5511), amplification of hdhfr::yfcu marker (SM; primers 4698/4699) and the original P. berghei 230p
(230p; primers 1637/5600). Primer location (black arrows) and product sizes are shown in A. For Southern analysis, PFG-separated chromosome were
hybridized using a 39UTR pbdhfr probe that recognizes the construct integrated into P. berghei 230p locus on chromosome 3 and the endogenous
locus of dhfr/ts on chromosome 7. (C) Diagnostic PCR and Southern analysis of PFG-separated chromosomes confirming correct integration of the
construct in the P. yoelii mother line GIMOPy17X:5 9 integration PCR (primers 6527/4770), 39 integration PCR (primers 4771/6528), amplification of
hdhfr::yfcu marker (primers 4698/4699) and the P. yoelii 230p original locus (primers 6529/6530). Primer location (grey arrows) and product sizes are
shown in A. For Southern analysis, chromosomal hybridization using a 39UTR pbdhfr probe recognizes the construct integrated into P. yoelii 230p
locus on chromosome 3 and the endogenous locus of dhfr/ts on chromosome 7.
doi:10.1371/journal.pone.0029289.g001
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introduction of a mCherry-expression cassette into the GIMOPbANKA mother line. Construct pL1628 containing the eef1a-mCherry-39pbdhfr cassette
(mCherry; red box) is integrated into the modified P. berghei 230p locus containing the hdhfr::yfcu selectable marker cassette (black box) by double
cross-over homologous recombination at the target regions (hatched boxes). Negative (Neg) selection with 5-FC selects for parasites (line 1645) that
have mCherry reporter introduced into the genome and the hdhfr::yfcu marker removed. Location of primers used for PCR analysis and sizes of PCR
products are shown (see Table S2 for primer sequences). (B) Diagnostic PCRs and Southern analysis of PFG-separated chromosomes confirms the
correct integration of construct pL1628 in line 1645 parasites shown by the absence of the hdhfr::yfcu marker and the presence of the mCherry gene:
59 integration PCR (59 int; primers 5510/4958), 39 integration PCR (39 int; primers 5515/5511), amplification of hdhfr::yfcu (SM; primers 4698/4699) and
the eef1a-mCherry (EF-mC; primers 3173/5514). Primer locations and product sizes are shown in A (primer sequences in Table S2). Hybridization of
separated chromosomes of GIMOPbANKA and line 1645 using a hdhfr probe recognizes the hdhfr::yfcu marker in the 230p locus on chromsomse 3 in
GIMOPbANKA but is absent in line 1645. Hybridization with 39UTR dhfr probe recognizes both modified the 230p locus on chromosome 3 (both marker
and mCherry expression cassettes contain the 39pbdhfr sequence) and the endogenous dhfr/ts gene on chromosome 7 as loading control.
(C) Fluorescence microscopy of a live mCherry-expressing trophozoite of line 1645; bright field (BF), DNA staining (Hoechst; Blue) and mCherry
expression (red). (D) FACS analysis of mCherry-expressing blood stages of line 1645. The percentage of mCherry-expressing parasites was performed
by FACS analysis on cultured blood stage. Mature schizonts (12–16 N) were selected based on their Hoechst fluorescent intensity (gate P2) and
mCherry-expressing schizonts were selected in gate P3 (right panel).
doi:10.1371/journal.pone.0029289.g002
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recombination. Plasmid pL1847 contains a fusion gene of gfp
and luciferase under the control of the P. berghei eef1a promoter
(Figure 4A). Integration of this construct will result in the
introduction of the gfp-luc expression cassette and a simultaneous
removal of the hdhfr::yfcu gene from GIMOPy17X (Figure 4A).
Transfection of GIMOPy17X parasites and negative selection was
performed as described above for GIMOPbANKA. Comparable to
results obtained with the transfection of GIMOPbANKA, two mice
(exp. 1970 & 1971) that were infected with GIMOPy17X
transfected parasites became positive at day 6 (parasitemia 1–
2%) after selection with the drug 5-FC. Analysis by fluorescence
microscopy showed that ,30% and ,70% of the parasites of line
1970 and 1971, respectively, were GFP positive (Figure 4B).
Southern analysis of PFG-separated chromosomes confirmed that
most drug-selected parasites of line 1971 had removed the
hdhfr::yfcu selectable marker (Figure 4C). We obtained three clones
of line 1971 and all three expressed luciferase as shown by in vivo
imaging of mice infected with 1971cl1-3 blood stages parasites
(Figure 4D). PCR analysis confirmed the correct integration of the
fusion gene gfp-luciferase and removal of hdhfr::yfcu (Figure 4E). The
results demonstrate that GIMO-transfection and the negative
selection procedure can be applied to P. yoelii in order to generate
parasites that express transgenes and are free of drug-selectable
markers. In addition, these marker-free P. yoelii 1971 cloned lines
(PyGFP-luccon), are excellent tools to quantitatively analyse P. yoelii
development in blood and liver stages using both in vivo and in vitro
luminescent assays as has been achieved with P. berghei reporter
parasites [17,18].
GIMO-transfection is a rapid and simple method for gene
complementation
Gene complementation is used to prove that the phenotype of
a gene deletion/modified parasite is the direct result of the gene
mutation and not a consequence of an unintended alteration of
the parasites genome [11]. Complementation is performed by
reintroduction of a wild-type copy of the gene into the genome of
a mutant in order to restore the wild-type phenotype, thereby
establishing the association of the phenotype to the deletion
genotype. We analysed whether GIMO-transfection can be used
for gene complementation using a published gene deletion
mutant of P. berghei with a defined phenotype. Complementation
of a mutant using GIMO-transfection requires that the mutant
contain the negative selectable marker yfcu in its genome. We
therefore choose to complement a P. berghei mutant (Dgr)w h i c h
lacks expression of glutathione reductase [19]. In this mutant, the
glutathione reductase (gr) has been deleted using a construct
containing the hdhfr::yfcu marker and the mutant becomes
arrested in the mosquito during oocyst development with a
complete absence of sporozoite production [19]. For comple-
mentation of the Dgr mutant we generated a restoration DNA-
construct by simply amplifying the gr gene from wild-type P.
berghei genomic DNA and therefore avoided any cloning steps.
Using the same primers that amplified the 59 and 39 targeting
regions for the DNA construct used to generate the Dgr gene
deletion mutant [19] (See Table S1), specifically the forward
primer of 59 targeting region and reverse primer of 39 targeting
region, a 2.8 kb PCR product that contained the complete gr
gene and both targeting regions was amplified by a high fidelity
proof reading polymerase (see Figure 5A). This PCR product was
used to transfect Dgr parasites, with the aim to introduce the
complete gr gene (‘gene insertion’) and thereby replacing the
deleted gr locus, containing the hdhfr::yfcu (‘marker out’) as shown
in Figure 5A. Selection of transfected parasites, using negative
selection was as described above for other GIMO-transfections,
and resulted in the selection of parasites (exp. 1761; Dgr(+gr)) in
which the deleted gr had been replaced by the wild-type gr gene as
confirmed by both diagnostic PCR and Southern analysis of
digested genomic DNA (Figure 5B). We next analysed the
phenotype of the complemented Dgr(+gr) parasites by comparing
oocyst and sporozoite development of Dgr(+gr)a n dDgr parasites
in Anopheles stephensi mosquitoes. As previously reported [19], Dgr
produced oocysts that abort development resulting in small
degenerated oocysts without any signs of sporoblast or sporozoite
formation (Figure 5C) at day 12 post infection (p.i.). The Dgr
infected mosquitoes are not able to infect naive mice at day 21
p.i. In contrast, the complemented Dgr(+gr) have normal
development in mosquitoes producing normal sized mature
oocysts, which contain sporozoites at day 12 p.i. and salivary
glands contained sporozoites at day 21 p.i. (Figure 5D). The
Dgr(+gr) sporozoites are infectious as shown by injection of 10
4
salivary gland sporozoites in two naı ¨ve Swiss mice. Both mice
developed a blood stage infection with a prepatency period of 5
Figure 3. The efficiency of GIMO-transfection to select marker-
free parasites that express mCherry. (A) Percentage of mCherry-
positive parasites in GIMO-transfection of GIMOPbANKA (shown in
Figure 2) after negative selection. The percentage of mCherry-positive
parasites in six independent transfections (1794–1799) was determined
by FACS analysis (see Figure 2D) and quantitative PCR (qPCR). By qPCR
the ratio of mCherry and hdhfr::yfcu marker positive parasites was
determined relative to the presence of a control gene hsp70, using
the 2
2DDCT method (primers used in qPCR are described in Table S2).
(B) Efficiency of selection of hdhfr::yfcu marker-free determined by
Southern analysis of PFG-separated chromosomes. Hybridization
performed using a mixture of two probes, one specific for pb25
(chromosome 5) and one for hdhfr (chromosome 3) showing the
efficiency of selecting hdhfr::yfcu marker-free parasites in the different
experiments.
doi:10.1371/journal.pone.0029289.g003
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10
4 wild type sporozoites. Genotype analysis of Dgr(+gr) blood
stage parasites after mosquito passage and sporozoite infection,
by diagnostic PCR and Southern analysis of digested genomic
DNA, confirmed that gr was indeed restored (i.e. complemented)
in the Dgr(+gr) parasites and no deletion mutants were present
(Figure 5B). The restoration of the phenotype of Dgr parasites
using a PCR-amplified construct in combination with negative
selection demonstrates that GIMO transfection is a fast method
for gene complementation (see also the Discussion section). In
addition it is a relatively simple method, requiring only PCR-
amplified DNA-constructs that can be used as the constructs do
not require a drug-selectable marker cassette.
Discussion
Genetic modification of malaria parasites is limited by the
paucity of drug-selection markers that permit selection of
transformed mutants, which in turn hampers the generation of
multiple genetic modifications in the same mutant. The novel
GIMO-transfection method reported in this study permits the
generation of mutants stably expressing heterologous proteins free
of drug-selectable markers, facilitating further genetic modification
of the transgenic parasites. In addition, it provides a fast and
simple way for gene complementation of gene deletion/mutation
mutants. We have generated reference mother lines and standard
‘knock-in’ constructs for both P. berghei ANKA and P. yoelii
Figure 4. Generation of a P. yoelii reporter line, PyGFP-luccon that is marker-free and expresses a fusion protein of GFP and
luciferase. (A) Schematic representation of the introduction of a gfp-luciferase-expression cassette into the GIMOPy17X mother line. Construct pL1847
containing the eef1a-gfp::luciferase-39pbdhfr cassette is integrated into the modified P. yoelii 230p locus containing the hdhfr::yfcu selectable marker
cassette (black box) by double cross-over homologous recombination at the target regions (hatched boxes). Negative selection with 5-FC results in
selection of parasites that have the gfp-luciferase reporter introduced into the genome and the hdhfr::yfcu marker removed. Location of primers used
for PCR analysis and sizes of PCR products are shown (see Table S2 for primer sequences). (B) Fluorescence microscopy of a live schizont of PyGFP-
luccon; bright field (BF), DNA staining (Hoechst; Blue) and GFP expression (green). (C) PFG-separated chromosomal Southern analysis of two
independent GIMO transfection parasite lines (exp. 1970 and 1971). Hybridization performed with a mixture of two probes, one specific for pb25
(chromosome 5) and the other for hdhfr (chromosome 3), demonstrating the efficiency of selection of hdhfr::yfcu ‘marker-free’ parasites in the
different experiments. (D) Analysis of luciferase-expression of blood stages of 3 clones of PyGFP-luccon (exp. 1971). Luciferase-activity was measured
by real time in vivo imaging of live mice with a parasitemia of 1–3%. (E) Diagnostic PCR analysis confirming correct integration of the gfp-luciferase
gene in PyGFP-luccon clones (exp. 1971): amplification of hdhfr::yfcu marker (SM, primers 4698/4699), 59 integration PCR (59 int, primers 6527/6812), 39
integration PCR (39 int, primers 6813/6528) and gfp-luc (primers 6814/6815). Primer location, product sizes are shown in A and primer sequences in
Table S2.
doi:10.1371/journal.pone.0029289.g004
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community. In GIMO-transfection of these mother lines,
transgenes are introduced in the 230p locus of both P. berghei
and P. yoelii. For P. berghei ANKA it has been shown that 230p is a
‘silent’ locus [20] and different reporter lines with transgenes
introduced in this locus has been generated that show wild-type
progression through the complete life-cycle [8,21]. Whether 230p
is also a ‘silent’ locus in P. yoelii has not been reported before. Our
observations of normal development of asexual stages, mosquito
development and sporozoite infectivity of the P. yoelii mother line
Figure 5. Gene complementation using GIMO-transfection. (A) Schematic representation of the re-introduction of the glutathione reductase
(gr) gene into the gr gene deletion mutant (Dgr, 1513cl1); 1513cl1 expresses the hdhfr::yfcu selectable marker (black box). Transfection with a 2.8 kb
PCR-fragment amplified from wild type genomic DNA (primers 4530/3681) containing the gr gene, as well as the 59- and 39-targeting sequences, was
used to re-introduce gr gene into the Dgr mutant. Negative selection with 5-FC selects for parasites that have the gr gene re-introduced into the
genome replacing the hdhfr::yfcu marker (line 1761; Dgr(+gr). Location of primers used for PCR analysis, sizes of PCR products, restriction enzyme sites
and sizes of the expected fragments in Southern analysis are indicated (see Tables S1 and S2 for primer sequences). (B) Diagnostic PCR analysis and
Southern analysis of restricted genomic DNA confirm correct integration of the PCR fragment and complementation in Dgr(+gr) parasites:
amplification of hdhfr::yfcu marker (SM; primers 4698/4699) and gr (ORF; primers 3742/3743). Primer location, product sizes are shown in A and primer
sequences in Table S2. Southern blot was hybridized with 39UTR gr probe (i.e. 39 targeting region). The localization of the restriction enzymes used
and the expected size of the fragments are shown in A: wt (wild type); Dgr (gr deletion mutants); Dgr(+gr) (complemented Dgr); mp (blood stages
after mosquito passage). (C) Oocyst development of Dgr and Dgr (+gr) parasites. Only small, aberrant oocysts with no signs of sporozoite formation
are present in Dgr infected mosquitoes at days 10–21 after feeding. In Dgr (+gr) infected mosquitoes sporozoite-containing oocysts with wild-type
morphology are visible at day 12. (E) Salivary gland sporozoites of Dgr(+gr) examined by immuno-fluorescence microscopy: bright field (BF) and anti-
CS antibody staining (CS, green).
doi:10.1371/journal.pone.0029289.g005
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introduce transgenes in P. yoelii.
Several P. berghei reference lines exist that express reporter
proteins, such as GFP and luciferase, and do not contain drug-
selection markers. Most of these parasites have been obtained by
FACS-sorting where GFP expression is used as the selectable
marker [8,9]. However, selection of transgenic fluorescent-
expressing parasites by FACS-sorting has been only reported for
selecting GFP-expressing parasites and not with parasites that
express other fluorescent proteins. In our hands, FACS-sorting of
GFP-expressing parasites is not a highly efficient selection method
as often the selected population consists of both mutant and wild
type parasites. Moreover, introducing a GFP-selection cassette
increases the size of the transfection construct. This limits the size
of the heterologous DNA that can be cloned into these vectors as it
is difficult to maintain Plasmodium transfection vectors with a size
larger than 14 kb in E. coli. Therefore, in comparison with FACS-
sorting, the GIMO-transfection system is a more flexible and
simpler system to introduce a wide range of heterologous genes
into the parasite genome with the additional advantage that
GIMO transfection constructs are far smaller since a selection-
marker cassette is not required.
In addition to the use of FACS-sorting for the generation of
marker-free P. berghei mutants a ‘marker-recycling’ method has also
been employed in P. berghei [10]. Specifically, transformed parasites
expressing the fusion gene hdhfr::yfcu are first selected by positive
selection with pyrimethamine; subsequently negative selection
with 5-FC is applied to select parasites that have lost the resistance
genes. The efficiency of selection of marker-free parasites is
dependent on the frequency of the loss of the hdhfr::yfcu marker
from the genome by homologous recombination and excision [10].
This method has been successfully used to generate marker-free
reporter lines [22], to introduce two independent genetic
modifications in the same parasite lines [22–24] and for
complementation [10]. However, this marker-recycling method
is relatively laborious and time consuming since it involves both
positive and negative selection procedures and two parasite-
cloning steps, a procedure requiring at least 9 weeks to complete.
Further, marker-recycling method requires at least 24 mice in
order to obtain a marker-free mutant (Figure 6A), in part a
consequence of essential cloning procedures [19,22]. In contrast,
the generation of marker-free mutants with GIMO-transfection
can be achieved in only 4 weeks and requires only 11 mice
(Figure 6A). The marker-recycling transfection constructs consist
of the hdhfr::yfcu drug-selectable marker cassette, a transgene
expression and two targeting sequences for integration into the
genome (See Figure S2A). In addition, they have two identical
regions of DNA sequence that can recombine (in the parasite
genome) and excise the selectable marker cassette. In contrast the
GIMO-constructs contain only the two genome targeting
sequences and the transgene expression cassette (see Figure S2
for a comparison of the marker-recycling and GIMO constructs).
The simple structure of GIMO constructs permits the cloning of
larger transgenes (the GIMO constructs are smaller as the
selectable marker cassette is absent) and improves the retention
of plasmids in bacteria as internally repetitive regions of AT-rich
Plasmodium DNA are absent. Further, after transfection with the
GIMO construct, the selection of integration mutants is improved
as no episomal construct DNA is maintained in the parasites and
negative selection kills parasites expressing yfcu.
GIMO-transfection is dependent on the transgene-expression
construct replacing the hdhfr::yfcu selection cassette present in the
mother line genome and the efficiency of the drug 5-FC to kill all
parasites where this integration has not occurred and that are still
expressing yFCU. Interestingly, in both P. berghei and P. yoelii
GIMO-transfection experiments we always observed that popula-
tions of 5-FC selected parasites contain (low numbers of) parasites
that still have the hdhfr::yfcu selection cassette in their genome.
Further research is required to determine whether these parasites
express yFCU but are able to survive 5-FC drug treatment or if
these parasites have lost expression of yFCU through the mutation
of hdhfr::yfcu selectable marker cassette. Experiments in our
laboratory are now focused on improving the application of
negative selection to mutant parasites in mice by providing 5-FC
in the drinking water, which may permit treatment with higher
concentrations of 5-FC and for longer periods. Notwithstanding
the presence of non-transformed parasites after selection of
GIMO-transfected parasites, the high percentages of transformed
parasites in the populations permit the collection of the desired
mutants by cloning. Using GIMO- transfection we have already
been able to successfully generate multiple marker-free lines that
express a variety of heterologous proteins (unpublished data JWL
and SK).
GIMO-transfection was used to generate a P. yoelii GFP-
luciferase reporter parasite and is the first report describing the use
of negative selection with 5-FC in combination with the yFCU
marker for genetic modification of this parasite species. Moreover,
the PyGFP-luccon line is the first P. yoelii reporter line that is
marker-free and can be easily further genetically modified. Similar
P. berghei reporter lines have been used to visualize and quantify
host parasite interactions in vivo [13,21,25,26], analysis of drug-
susceptibility [17,27,28] and in vivo quantification of liver stage
development [18,29].
In this study we demonstrate that GIMO-transfection can not
only be used to introduce heterologous genes but also is a fast and
simple method for gene complementation. Restoration of the wild
type phenotype by gene complementation is the most optimal
strategy to show that a mutant phenotype is the result of the
intended deletion (or mutation) and is not due to unrelated
alterations in the parasite genome [2,11]. Genetic complementa-
tion has not been widely applied in Plasmodium due to difficulties in
making successive genetic modifications in the same parasite, and
to problems inherent in cloning full-length AT-rich Plasmodium
genes into bacterial plasmid vectors [11]. Till now two methods
have been used to complement gene deletion mutants in P. berghei.
The first method re-introduces the wild-type gene using a
construct containing hdhfr as a positive selectable marker [30,31].
The encoded protein confers resistance to WR99210, and can be
used to transfect gene deletion mutants that already contain the
pyrimethamine resistance markers dhfr/ts from P. berghei or the dhfr
from Toxoplasma gondii (tgdhfr) [7]. However, selection with
WR99210 is not straightforward because of problems with
dissolving this drug and because there is a reduced sensitivity to
WR99210 of parasites that already contain the dhfr/ts or tgdhfr
marker [7,10] (unpublished observations CJJ). The second
complementation method is based on the marker-recycling, as
described above. Gene deletion mutants (containing hdhfr::yfcu) are
first subjected to negative selection to select for marker-free
parasites, cloned and then transfection is performed with
constructs containing the gene for complementation and a drug
selection cassette [10] (see Figure S3A). This method requires
generally 7 weeks and 14 mice to perform (Figure 6B). In contrast,
complementation with GIMO-transfection takes only 2 weeks and
1 mouse (Figure 6B). Not only is the GIMO method much faster,
requiring far fewer mice, but also a big advantage is that a simple
PCR amplicon containing the wild-type gene can be used for
complementation as no drug selectable needs to be used in the
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and GIMO methods).
In summary, we have developed a novel method that simplifies
and speeds up both the generation of marker-free parasites
expressing heterologous proteins and for the genetic complemen-
tation of gene deletion/mutation mutants. Moreover the applica-
tion of this method greatly reduces the numbers of animals
required to generate and complement mutants. We have also
generated the first marker-free P. yoelii reporter line and
established the successful use of negative selection in transfection
of P. yoelii parasites. The GIMO-transfection is a simple, fast and
efficient approach to generate mutants permissive to subsequent
genetic modification. Therefore we recommend that, where
possible, transfection of P. berghei and P. yoelii parasites be
performed with constructs that contain the postive-negative
selectable marker cassette, hdhfr::yfcu. The presence of this marker
in mutants permits subsequent GIMO transfection that not only
simplifies the creation of additional deletions or modifications but
also gene complementation experiments. A recent study has
reported high-throughput, genome wide and highly efficient
‘recombineering’ system, for high-throughput, genome wide and
highly efficient generation of gene targeting constructs [12]. This
Figure 6. Compared to the marker-recycling method GIMO-transfection is faster and requires fewer animals to both generate
marker-free gene insertion (GI) mutants and to complement gene deletion mutants. (A) Number of weeks (w) and number of mice (m)
needed to generate ‘marker-free’ gene insertion mutants expressing transgenes using GIMO-transfection (right) and using the marker-recycling
method (left). (B) Number of weeks (w) and number of mice (m) needed for complementation of a gene deletion mutant using GIMO-transfection
(right) and using the marker-recycling method (left).
doi:10.1371/journal.pone.0029289.g006
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by ensuring all these targeting constructs have a positive-negative
(hdhfr::yfcu) selectable marker cassette. Consequently all resulting
mutants would be receptive to GIMO transfection thereby
permitting further modification (e.g. reporter protein expression)
and complementation.
Materials and Methods
Experimental animals and parasites
Female Swiss OF1 mice (6–8 weeks old; Charles River/Janvier)
were used.
All animal experiments of this study were approved by the
Animal Experiments Committee of the Leiden University Medical
Center (DEC 07171; DEC 10099). The Dutch Experiments on
Animal Act is established under European guidelines (EU directive
no. 86/609/EEC regarding the Protection of Animals used for
Experimental and Other Scientific Purposes).
Two reference rodent malaria parasite lines were used: P. berghei
ANKA line cl15cy1 [14] and P. yoelii 17XNL (clone 1.1) parasite
line [32].
Generation of GIMO mother lines in P. berghei ANKA and
P. yoelii 17XNL
To generate the GIMO mother line in P. berghei, a DNA-
construct pL1603 was generated for integration into the 230p gene
(PBANKA_030600) by cloning the 59 and 39 regions of 230p as
previously described [8]. The targeting sequences were amplified
from genomic DNA using primer sets 5585/5586 and 5587/5588
(See Table S1 for the sequence of all primers) and cloned into the
restriction sites of HindIII/KspI and Asp718I/EcoRI of the
standard cloning vector pL0034 (MRA-849, www.mr4.org), which
contains the hdhfr::yfcu selectable marker under the control of the
eef1a promoter [10]. The hdhfr::yfcu marker is a fusion gene of the
positive selection marker human dihydrofolate reductase and the
negative selection marker which is a fusion gene of yeast cytosine
deaminase and uridyl phosphoribosyl transferase [10]. Prior to transfec-
tion the DNA-construct pL1603 was linearized with HindIII and
EcoRI.
To generate the GIMO mother line in P. yoelii, a modified two
step PCR method [33] was used to generate DNA-construct
pL1805 for integration into the 230p gene (PY03857) of P. yoelii
(Figure S1A). In the first PCR reaction two fragments (59- and 39-
targeting sequences, both ,1 kb) of 230p were amplified from P.
yoelii 17XNL genomic DNA with the primer sets 6523/6524 and
6525/6526 (Table S1). Primers 6524 and 6525 have 59- extensions
homologues to the hdhfr::yfcu selectable marker cassette (CATC-
TACAAGCATCGTCGACCTC in 6524 and CCTTCAA-
fTTTCGGATCCACTAG in 6525). This selectable marker
cassette was excised by digestion with XhoI and NotI from a
plasmid (pL0048) that contains the P. berghei eef1a-hdfhr::yfcu-
39dhfr/ts (i.e. promoter-drug selectable marker-39 terminator
sequence) selection cassette. Primers 6523 and 6526 have 59-
terminal extensions with an anchor-tag suitable for the second
PCR reaction. In the second PCR reaction, the amplified 59- and
39- targeting sequences were annealed to either side of the
selectable marker cassette, and the joint fragment was amplified by
the external anchor-tag primers 4661/4662, resulting in the PCR-
based targeting construct with an expected size of 4.7 kb (2.7 kb of
the selectable marker cassette plus two targeting sequences of
1 kb). Before transfection, the PCR-based construct was digested
with Asp718I and ScaI (in primers 6523 and 6526, respectively) to
remove the ‘anchor-tag’ and with DpnI that digests any residual
pL0048 plasmid.
Transfection in P. berghei ANKA and P. yoelii 17XNL, selection
and cloning of the mother lines were performed by standard
procedures described for transfection of P. berghei [14]. DNA-
construct pL1603 was introduced into P. berghei generating mother
line, GIMOPbANKA (1596cl1), and DNA construct pL1805 was
introduced into P. yoelii generating mother line, GIMOPy17X
(1923cl1). Correct integration of the constructs was verified by
diagnostic PCR analysis (see Table S2 for primers used) and
Southern blot analysis of pulse-field gel (PFG) electrophoresis-
separated chromosomes probed with the 39 untranslated region
(UTR) of the dhfr/ts gene of P. berghei.
Generation of basic constructs without selection marker
and that target the 230p locus of the GIMOPbANKA and
GIMOPy17X mother lines
To generate a basic P. berghei 230p-targeting construct (pL0043),
the 230p targeting regions as well as the ampicillin resistance gene
were amplified from plasmid pL1063 (MRA-852, www.mr4.org)
using primers 5116/5117 (Table S1). A multiple cloning site
(MCS) was amplified from pCRII-Blunt-TOPO vector (Zero
Blunt TOPO PCR Cloning Kit, Invitrogen, Groningen, The
Netherlands) using M13 forward and reverse primers. The two
PCR products were digested with Asp718I and NotI restriction
enzymes and ligated together creating the targeting construct
pL0043.
A basic P. yoelii 230p-targeting construct (pL1849) was generated
using a modified 2-step PCR method (Figure S1B). In the first
PCR reaction, 59-and 39- targeting sequences (both ,1 kb) of 230p
were amplified from P. yoelii 17XNL genomic DNA with the
primer set 6523/6534 and 6525/6526 (Table S1). As described
above these primers contain 59- extensions homologues to the
hdhfr::yfcu selectable marker cassette and 59-terminal extensions
with an anchor-tag suitable for the second PCR reaction. A 55 nt
oligo (oligo 6598; GAGGTCGACGATGCTTGTAGATGC-
CCGGGCCTTCAATTTCGGATCCACTAG) containing a
XmaI restriction site flanked by 2 sequences homologues to the
hdhfr::yfcu selectable marker cassette was used to join the two 230p
targeting regions (Figure S1B). In the second PCR reaction an
fragment containing both 230p targeting sequences interrupted by
the XmaI site was amplified, using the external anchor-tag primers
4661/4662, resulting in the PCR product of ,2 kb. The PCR
product was cloned into TOPO TA vector (TOPO TA CloningH
Kit, Invitrogen, Groningen, The Netherlands) resulting in
construct pL1849.
Generation of a mCherry reporter test construct and
GIMO-transfection in the P. berghei mother line,
GIMOPbANKA
A test construct (pL1628) for GIMO-transfection in the
GIMOPbANKA mother line was generated by transferring the
mCherry-expression cassette (59pbeef1a-mCherry-39pbdhfr) from plas-
mid pL0017-mCherry [34] into the basic 230p targeting construct
pL0043 (see above) using restriction sites EcoRV/Asp718I. This
plasmid was linearized with KspI before transfection. Transfection
was performed as described [14]. Transformed parasites were
selected by negative selection by the administration the drug 5-FC
(Sigma) to mice infected with transfected parasites. Specifically;
0.4 g/kg bodyweight of 5-FC (stock: 20 mg/ml in 16PBS)
administered by intra-peritoneal injection; one dose per day; for
a period of 4 days, starting at 24 hours after transfection.
Transformed parasites were collected at day 6/7 (infected tail
blood) for phenotype analysis by fluorescence microscopy and
FACS (see below) and at day 7/8 (infected heart blood) for
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Southern analysis of PFG-separated chromosomes [14].
Generation of a constitutively GFP-luciferase expressing
P. yoelii (PyGFP-luccon) reporter line using GIMO-
transfection
A construct (pL1847) for GIMO-transfection in the GIMOPy17X
mother line was generated by cloning an PCR-amplified GFP-
luciferase expression cassette into the XmaI site of the basic P. yoelii
230p targeting construct pL1849 (see above). The GFP-luciferase
expression cassette (59 eef1a-gfp::luciferase-39pbdhfr) was amplified
from pL1603 (MRA-852, www.mr4.org) using primers 6599 and
6600.
Transfection of GIMOPy17X parasites and negative selection of
transformed parasites was performed as described above for
transfection of GIMOPbANKA. Transformed parasites were
collected for genotype analyses using standard methods of
diagnostic PCR and Southern analysis of PFG-separated chro-
mosomes [14]. Cloned parasites were analysed for luciferase
expression using the in vivo imaging technology described below.
Gene complementation using GIMO transfection
Gene complementation was performed using the published
glutathione reductase deletion mutant (Dgr)o fP. berghei [19]. In this
mutant (Dgr4; 1531cl1) the glutathione reductase (gr) gene has been
deleted by a replacement construct (pL1538) that contains the
postive-negative hdhfr::yfcu selectable marker cassette [19]. The
pL1538 construct contains 59 and 39 targeting regions of gr.W e
used two of the primers that have been used to generate the
replacement construct pL1538 to amplify gr gene from P. berghei
genomic DNA using a proof reading polymerase (PhusionH,
Finnzymes, Espoo, Finland). These primers (4049; forward primer
for 59 targeting region and 3681; reverse primer for 39 targeting
region) amplify the complete gr gene including the 59 and 39
targeting regions (see Table S1 for primer sequences). PCR
resulted in amplification of a 2.8 kb fragment which was used to
transfect Dgr parasites using standard transfection procedures [14].
Transformed parasites were selected by negative selection as
describe above. Transformed parasites were collected for genotype
analyses using standard methods of diagnostic PCR and Southern
analysis of digested genomic DNA. Analysis of the phenotype of
the complemented parasites, Dgr(+gr), was analysed by mosquito
transmission experiments (see below).
Fluorescence microscopy and FACS analysis
For analysis of GFP- or mCherry- expression in blood stages of
transgenic parasites, infected tail blood was collected in PBS and
examined by microscopy using a Leica DMR fluorescent
microscope with standard GFP and Texas Red filters. Parasites
nuclei were labeled by staining with Hoechst-33258 (2 mmol/L,
Sigma, NL). Images were recorded with the digital camera
CoolSNAP HQ
2 (Photometrics, NL) and processed with the
ColourProc software [35]. The percentage of blood stages
parasites that express mCherry was determined by FACS analysis
of cultured blood stages. In brief, infected tail blood (10 mL) with a
parastemia between 0.5 and 1% was cultured overnight in 1 mL
complete RPMI1640 culture medium at 37uC under standard
conditions for the culture of P. berghei blood stages [36]. Cultured
blood samples were then collected and stained with Hoechst-
33258 (2 mmol/L, Sigma, NL) for 1 hr at 37uC in the dark and
analysed using a FACScan (BD LSR II, Becton Dickinson, CA,
USA) with filter 440/40 for Hoechst signals and filter 610/20 for
mCherry fluorescence. For FACS analysis the population of
mature schizonts were selected based on the their Hoechst-
fluorescence intensity [37]; see gate P2 in the left panel of
Figure 2D. The percentage of mCherry-expressing parasites was
calculated by dividing the number of mCherry-positive schizonts
(gate P3 in right panel of Figure 2D) by the total number of
schizonts (gate P2).
Quantitative real-time PCR (qPCR) analysis of
transformed parasites
Genomic DNA extracted from blood stage parasites was used
for qPCR analysis. To determine the ratio of transformed/non-
transformed parasites in the selected parasite populations, PCR
amplifications of the mCherry gene (only present in transformed
parasites) and the hdhfr::yfcu selectable marker (only present in
non-transformed) were carried out using the QuantiTect SYBR
Green PCR Kit (Qiagen, Hilden, Germany) on a CFX96 thermal
cycler (Bio-Rad Laboratories, The Netherlands). The housekeep-
ing gene, P. berghei hsp70, was used as reference (see Table S2 for
primers used). Real-time PCR cycle thresholds (CT) were
calculated as the average of triplicate analyses (per genomic
DNA from transgenic parasite). The ratio between mCherry and
hdhfr::yfcu was calculated by the 2
2DDCT method relative to hsp70
[16]. The amplification efficiencies of mCherry and hsp70 did not
violate assumptions of the DDCT method (data not shown).
Real time in vivo imaging of the PyGFP-luccon reporter
parasites in whole bodies of live mice
Expression of luciferase and imaging of distribution of
luciferase-expressing PyGFP-luccon parasites in whole bodies of
live mice was determined by measuring bioluminescent activity
using the IVIS100 in vivo imaging system (Caliper Life Sciences,
USA) as described previously [21,38]. Bioluminescence of blood
stage parasites was imaged in Swiss mice with asynchronous
infections of PyGFP-luccon parasites at a parasitemia of 0.5–2%.
Analysis of the phenotype of Dgr and complemented
Dgr(+gr) parasites during mosquito transmission
Infection of Anopheles stephensi mosquitoes with Dgr and Dgr(+gr)
parasites as well as determination of production of oocysts and
salivary gland sporozoites was performed as previously described
[39]. Infectivity of sporozoites was tested by intravenous injection
of Swiss OF1 mice with 10
4 hand dissected salivary gland
sporozoites. The prepatent period was determined by light
microscopy analysis of Giemsa-stained thin smears of tail blood.
Prepatency (measured in days after sporozoite inoculation) is
defined as the day when parasitemia reaches 0.5–2%.
Indirect Immunofluorescence assay
10
4 Dgr(+gr) salivary gland sporozoites in 10 mL were allowed to
adhere to polylysine coating slides, fixed for 15 minutes with 4%
PFA, and washed 365 minutes with PBS. Sporozoites were then
permeabilized with 0.5% Triton-X100 for 15 minutes followed by
a3 65 minutes wash with PBS. Slides were blocked 30 minutes at
room temperature in 10% FCS and incubated over night with
polyclonal rabbit anti-CS antiserum [40] (dilution 1:1000, kindly
provided by Dr M. Yuda) at 4uC. Slides were washed
365 minutes in PBS and incubated with donkey anti-rabbit,
Alexa 488-conjugated secondary antibody (dilution 1:500), 1 hr in
room temperature. Slides were washed 365 minutes in PBS, and
then incubated 15 minutes with Hoechst 33342 in room
temperature. Prior to mounting, slides were washed for 5 minutes
and analysed with were analyzed using a Leica DMR fluorescence
microscope at 10006magnification.
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Figure S1 Generation of P. yoelii 230p targeting con-
structs using a PCR method. A. The DNA construct
(pL1805) used to generate the P. yoelii GIMO mother line was
created using a modified two-step PCR method. In the first PCR
reaction, 59- and 39- targeting sequences of 230p were amplified
from P. yoelii 17XNL genomic DNA with the primer sets 6523/
6524 and 6525/6526 (Table S1). Primers 6524 and 6525 have 59-
extensions homologues to the hdhfr::yfcu selectable marker cassette
(hatched boxes). This selectable marker cassette was excised from
plasmid pL0048 digested with XhoI and NotI. Primers 6523 and
6526 have 59-terminal extensions (black boxes) for the second
PCR reaction. In the second PCR reaction, the 59- and 39-
targeting sequences annealed to either side of the selectable
marker cassette, and the joint fragment was amplified by the
external anchor-tag primers 4661/4662. Before transfection, the
PCR construct was digested with Asp718I and ScaI to remove the
anchor-tag and with DpnI to digest any residual pL0048 plasmid.
B. The basic P. yoelii 230p targeting construct (pL1849) was
generated by a modified PCR method. In the first PCR reaction,
59-and 39- targeting sequences with homologous sequences
(hatched boxes) and anchor-tag sequences (black boxes) were
amplified as shown in A. Oligo no. 6598 that contains the joint
homologous sequences interrupted by an XmaI site (hatched
boxes) was used as template for the second PCR reaction. Using
the external anchor-tag primers 4661/4662, a PCR product
containing both targeting sequences now with the XmaI site in the
middle was amplified and subsequently cloned into TOPO TA
vector resulting in construct pL1849.
(EPS)
Figure S2 Schematic representation of the generation of
marker-free gene insertion (GI) mutants using GIMO-
transfection method or using the marker-recycling
method. A. Generation of marker-free gene insertion mutants
expressing a gene of interest (GOI; grey box) using the standard
marker-recycling method. The construct containing the hdhfr::yfcu
selectable maker (black box) flanked by the recombination
sequences (rc, shaded boxes) targets the 230p locus by double
cross-over homologous recombination at specific target regions
(hatched boxes). GI mutants are obtained after transfection, using
positive selection with pyrimethamine and then cloning. Subse-
quently, marker-free GI mutants are selected by negative selection
using 5-FC. Only those mutants that have ‘spontaneously’ lost the
hdhfr::yfcu marker from their genome, achieved by a homologous
recombination/excision (see arrow), survive negative selection. B.
Generation of marker-free gene mutants that express a GOI (grey
box) using GIMO-transfection. The construct that contains no
selectable marker cassette and targets the modified GIMO mother
line 230p locus that contains the hdhfr::yfcu (black box) marker, by
double cross-over homologous recombination at the target regions
(hatched boxes). Marker-free GI mutants, that have GOI
expression cassette introduced into the 230p locus replacing the
hdhfr::yfcu marker, are obtained by negative selection with 5-FC.
(EPS)
Figure S3 Schematic representation of gene comple-
mentation using GIMO-transfection and the marker-
recycling method. A. Gene deletion and complementation
using the marker-recycling method. The gene deletion construct,
containing the hdhfr::yfcu selectable maker (black box) flanked by
the recombination sequences (rc; shaded boxes), targets the gene of
interest (GOI) by double cross-over homologous recombination at
the target regions (hatched boxes). Gene deletion mutants are
obtained after transfection and positive selection with pyrimeth-
amine, and cloning. Subsequently, marker-free gene deletion
mutants are selected by negative selection using 5-FC. Only those
mutants that have ‘spontaneously’ lost the hdhfr::yfcu marker from
their genome, achieved by a homologous recombination/excision
event (see arrow), survive negative selection.Complementation of
the (cloned) marker-free gene deletion mutant is performed using
constructs that contain a GOI expression cassette and a positive
selectable marker cassette. These constructs can target either the
original deleted locus or a locus that is redundant or functionally
silent. Complemented parasites are selected by positive selection.
B. Gene deletion and complementation using the GIMO-
transfection method. The gene deletion construct containing the
hdhfr::yfcu selectable maker fusion (black box) targets the GOI by
double cross-over homologous recombination at specific target
regions (hatched boxes). Gene deletion mutants are obtained after
transfection using positive selection with pyrimethamine and then
cloning. These constructs do not include recombination (rc)
sequences (see A). Complementation of the gene deletion mutant is
performed using a PCR fragment amplified from genomic DNA
using the same outer primers used to generate the gene deletion
construct (i.e. the forward primer of the 59UTR and the reverse
primer of 39UTR, indicated by arrows). Integration of the PCR
fragment by homologous recombination restores the deleted gene
locus replacing the hdhfr::yfcu maker. Complemented parasites are
selected by negative selection.
(EPS)
Table S1 Primers used for DNA construct generation.
(DOC)
Table S2 Primers used for genotype analysis.
(DOC)
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